Welcome to our dedicated page for Terra Innovatum Global N.V. SEC filings (Ticker: NKLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Terra Innovatum Global N.V. (NASDAQ: NKLR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, registration statements, and exhibits related to its micro-modular nuclear reactor business. As an emerging growth company incorporated in the Netherlands and listed on The Nasdaq Stock Market LLC, Terra Innovatum files documents with the U.S. Securities and Exchange Commission that describe its corporate structure, risk factors, business combination history, and progress as a developer of the SOLO™ Micro-Modular Reactor.
Among these filings, investors can review current reports on Form 8‑K, such as disclosures about letters of intent with customers, business combination milestones, and other material events. For example, a Form 8‑K identifies Terra Innovatum Global N.V. as the registrant, confirms its Nasdaq ticker symbol NKLR, and references a press release regarding the execution of a letter of intent with a customer. Over time, the company’s quarterly and annual reports (Forms 10‑Q and 10‑K, when filed) are expected to provide more detailed information on its financial position, regulatory strategy with the U.S. Nuclear Regulatory Commission, and the status of its SOLO reactor development and commercialization plans.
On Stock Titan, these filings are complemented by AI-powered summaries designed to help readers interpret key points in lengthy documents. Users can quickly see the main topics of a filing, such as updates on NRC engagement, manufacturing agreements with partners like ATB Riva Calzoni, or changes in capital structure following a business combination. The platform also surfaces insider transaction reports on Form 4, proxy materials on executive and board matters when available, and other SEC forms that contribute to a fuller picture of NKLR’s regulatory and corporate history.
By combining real-time EDGAR updates with concise AI explanations, this page helps investors, analysts, and researchers navigate Terra Innovatum’s SEC filings and understand how its disclosures relate to the development of the SOLO micro-modular reactor.
Terra Innovatum Global N.V. (NKLR) filed a prospectus supplement to its Form S-1 registering up to 5,475,593 Ordinary Shares issuable upon exercise of warrants, up to 94,804,436 Ordinary Shares, and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of outstanding preferred shares. On August 14, 2026, its Ordinary Shares closed at $6.09 on Nasdaq.
The attached current report describes the appointment of Katherine Williams as Chief Financial Officer of the U.S. subsidiary and as an executive director/CFO of Terra Innovatum Global N.V. Her package includes a base salary of $465,000, a one-time $40,000 sign-on bonus, and an annual performance-based MBO bonus opportunity between 50% and 250% of base salary, plus severance and change-in-control protections providing up to 18 months of salary, target bonus, 18 months of healthcare coverage, equity-vesting acceleration, and up to $30,000 of outplacement services in certain termination scenarios.
Terra Innovatum Global N.V. (NKLR) reported that its U.S. subsidiary, Terra Innovatum Corp., entered into an Employment Agreement with Katherine Williams, under which she will serve as Chief Financial Officer. Her term runs until after the 2028 annual general meeting relevant to the 2027 financial statements, subject to earlier termination or extension.
Ms. Williams will receive a base salary of $465,000, a one-time signing bonus of $40,000, and an annual performance-based MBO Bonus ranging from 50% to 250% of base salary depending on performance and form of payment. For qualifying terminations, she is entitled to salary-based severance, bonus elements, extended healthcare, and equity-vesting benefits, with enhanced cash and benefits if the termination occurs within 12 months after a change in control. She was also appointed an executive director and CFO of Terra Innovatum Global N.V. under a Directorship Agreement that runs to the 2028 AGM and provides EUR 200,000 in annual director compensation, which is paid to the U.S. subsidiary rather than to her.
Terra Innovatum Global N.V. is updating a prior S-1 prospectus to cover up to 5,475,593 ordinary shares issuable upon exercise of warrants, 94,804,436 ordinary shares, and 40,200,000 ordinary shares issuable upon mandatory conversion of outstanding preferred shares. The company is pre-revenue, developing its 1 MWe SOLO micro‑modular nuclear reactor and targeting first deployment by 2028. For the quarter ended June 30 2026, it reported a net loss of $18,044 thousand and a six‑month net loss of $25,150 thousand, driven by higher general and administrative and development costs and large non‑cash fair value losses on share‑settled contingent liabilities and warrant liabilities. Cash and cash equivalents were $91,055 thousand against total liabilities of $214,015 thousand, resulting in a shareholders’ deficit of $(115,495) thousand. Management prepares the accounts on a going‑concern basis but discloses material weaknesses in internal control over financial reporting and continues to invest in regulatory engagement and engineering for the SOLO reactor.
Terra Innovatum Global N.V., a pre-revenue developer of the SOLO micro‑modular nuclear reactor, reported a larger net loss and a deeper shareholders’ deficit for the quarter and six months ended June 30, 2026. For the quarter, net loss was $18.0 million versus $1.1 million a year earlier; for the first half, net loss was $25.2 million compared with $2.6 million in 2025, driven by sharply higher general and administrative and development costs plus large non‑cash fair‑value charges.
Total assets were $98.5 million, including cash and cash equivalents of $91.1 million. Total liabilities were $214.0 million, dominated by a $196.5 million share‑settled contingent liability tied to de‑SPAC milestone instruments and $10.5 million of warrant liabilities, resulting in a shareholders’ deficit of $115.5 million. Net cash used in operating activities was $8.8 million in the first half. The company remains in development, with no revenue and a target commercialization timeline around 2028 for its SOLO reactor, and discloses ongoing early‑stage, regulatory, funding, and macroeconomic risks. Management prepared the accounts on a going‑concern basis but acknowledges existing material weaknesses in internal control over financial reporting and plans remediation efforts.
Terra Innovatum Global N.V. filed a Prospectus Supplement No. 3 to register up to 94,804,436 Ordinary Shares, including up to 5,475,593 Ordinary Shares issuable upon exercise of warrants and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of outstanding preferred shares. The supplement attaches a Form 8-K dated July 2, 2026 and updates the Prospectus dated December 15, 2025.
The company notes its Ordinary Shares trade on Nasdaq under the symbol NKLR; the closing price reported on Nasdaq on July 2, 2026 was $4.62. The supplement should be read with the Prospectus and prior amendments.
Terra Innovatum Global N.V. amends its S-1 prospectus to register up to 94,804,436 Ordinary Shares. The supplement specifically lists up to 5,475,593 Ordinary Shares issuable upon exercise of warrants and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of outstanding preferred shares. The prospectus supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026 and notes the Company’s Nasdaq listing under the symbol NKLR; the closing price on July 2, 2026 was $4.62 per share. The Company reported cash and cash equivalents of $96,701 and total ordinary shares issued and outstanding of 110,500,908 as of June 29, 2026. This supplement updates the prospectus and must be read together with the Prospectus dated December 15, 2025.
Terra Innovatum Global N.V. registers up to 94,804,436 Ordinary Shares under a Prospectus Supplement No. 1 to its Registration Statement on Form S-1. The supplement also registers up to 5,475,593 Ordinary Shares issuable upon exercise of warrants and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of preferred shares.
The Prospectus Supplement attaches the company’s Annual Report on Form 10-K filed on June 16, 2026 and updates the Prospectus dated December 15, 2025. The cover disclosure notes a Nasdaq closing price of $4.62 on July 2, 2026 and states there were 110,500,908 ordinary shares outstanding as of March 31, 2026.
Terra Global N.V. reported a governance change as its Board appointed Joanna Lohkamp as an interim non-executive director, effective July 1, 2026. She will also serve on the Audit Committee and chair the Remuneration Committee until the next annual general meeting of shareholders.
The company states there are no arrangements or understandings behind her selection, no family relationships with current directors or executives, and no material related-party transactions requiring disclosure. This emphasizes her independence within the board structure and key oversight committees.
Terra Innovatum Global N.V., a pre‑revenue nuclear technology company developing its SOLO micro‑modular reactor, reported a net loss of $7,106 thousand for the three months ended March 31, 2026, compared with $1,448 thousand a year earlier. The wider loss reflects sharply higher general and administrative expenses of $5,396 thousand and development costs of $1,238 thousand as the company scales public‑company infrastructure and engineering work.
Cash and cash equivalents were $96,701 thousand at March 31, 2026, with net cash used in operating activities of $3,856 thousand for the quarter. The balance sheet includes a sizable share‑settled contingent liability of $185,860 thousand and warrant liabilities of $9,949 thousand tied to the SPAC-related capital structure. Management prepared the accounts on a going concern basis but disclosed that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
Terra Innovatum Global N.V., a Dutch holding company headquartered in Lucca, Italy, files its annual report describing a pre-revenue, early-stage micro‑modular nuclear business built around its SOLO reactor. The company completed a business combination with GSR III Acquisition Corp. in October 2025, after which its ordinary shares began trading on Nasdaq under the symbol NKLR.
SOLO is designed to deliver 1MWe of power plus up to 4MW of low‑temperature heat or 5MW of high‑temperature steam, operate for 15 years without refueling, and potentially reach a 45‑year lifecycle. Terra targets first commercial deployment by 2028, focusing on industrial, data center, logistics, medical and underserved community applications.
The report highlights substantial risks: no revenue to date, an accumulated deficit of approximately $607.3 million as of December 31, 2025, reliance on future financing, complex nuclear regulation, evolving public perception of nuclear power, supply‑chain and cybersecurity exposure, and unresolved long‑term nuclear waste and fuel storage issues.